Literature DB >> 2164382

Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich.

H Schuster1, G Rauh, B Kormann, T Hepp, S Humphries, C Keller, G Wolfram, N Zöllner.   

Abstract

It has recently been suggested that a substitution of glutamine for arginine at residue 3500 of apolipoprotein (apo) B-100 causes familial defective apo B-100 (FDB), an autosomal, dominantly inherited disorder, which leads to increased serum cholesterol levels. From a sample of 243 patients from Munich with type IIa hyperlipoproteinemia (HL), we have identified eight individuals with the apo B-100 arginine(3500)----glutamine mutation. In a group of 57 subjects with defective low density lipoprotein receptor (LDLR), no mutant apo B alleles were detected. The frequency of FDB in patients with type IIa HL was estimated to be 3%. In the kindreds of three of the probands, 10 additional carriers of the apo B mutation were identified. Clinical and biochemical data reveal a striking similarity between patients with FDB and those with a defect in the LDLR gene. Our data support previous findings that FDB is a serious disorder causing premature atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164382     DOI: 10.1161/01.atv.10.4.577

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  19 in total

1.  First International Workshop on Familial Defective apo B-100, Munich, November 1991.

Authors:  H Schuster; S Humphries; G Rauh; C Keller
Journal:  Clin Investig       Date:  1992-10

2.  Approach to identification of a point mutation in apo B100 gene by means of a PCR-mediated site-directed mutagenesis.

Authors:  E I Schwartz; S P Shevtsov; A P Kuchinski; O V Plutalov
Journal:  Nucleic Acids Res       Date:  1991-07-11       Impact factor: 16.971

3.  Familial hypercholesterolaemia.

Authors:  A David Marais
Journal:  Clin Biochem Rev       Date:  2004-02

4.  The polymorphism ApoB/4311 in patients with myocardial infarction and controls: the ECTIM Study.

Authors:  J F Moreel; G Roizes; A E Evans; D Arveiler; J P Cambou; C Souriau; H J Parra; E Desmarais; J C Fruchart; P Ducimetière
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

5.  Use of DNA haplotype analysis in diagnosis of familial hypercholesterolaemia in 31 German families.

Authors:  H Schuster; G Rauh; C Gerl; C Keller; G Wolfram; N Zöllner
Journal:  J Med Genet       Date:  1991-12       Impact factor: 6.318

Review 6.  Familial defective apolipoprotein B-100: a cause of hypercholesterolemia and early coronary heart disease.

Authors:  B A Nassar
Journal:  CMAJ       Date:  1993-02-15       Impact factor: 8.262

7.  Use of the single-strand conformational polymorphism method to detect recurrent and novel mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolaemia: detection of a novel mutation Asp200-->Gly.

Authors:  V Gudnason; Y T Mak; J Betteridge; S N McCarthy; S Humphries
Journal:  Clin Investig       Date:  1993-04

8.  RFLPs of the LDL-receptor gene: their use in the diagnosis of FH and in evaluation of different levels of gene expression on normal subjects.

Authors:  S Bertolini; D A Coviello; P Masturzo; E Zucchetto; N Elicio; R Balestreri; G Orecchini; S Calandra; S Humphries
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

9.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

10.  Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.

Authors:  P S Hansen; H Meinertz; L U Gerdes; I C Klausen; O Faergeman
Journal:  Clin Investig       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.